TICKERNERD
Menu
IMRXIMRXHealthcare · Biotechnology

IMRX Stock Forecast: Immuneering Corp. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$4.00
+4.44% on the day

The 7 Wall Street analysts covering Immuneering Corp. hold a median 12-month price target of $16 — +287.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$247.8M
Ticker Nerd rank
36/ 100
Median analyst target
$16
Analysts covering
7
Revenue$0.0
Operating income−$19.0M
Net income−$17.3M
Free cash flow−$16.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.0%
1M
−3.8%
YTD
−39.2%
1Y
−38.4%
From 52W high
−52.0%
From 52W low
+17.0%
$3.42
$8.33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immuneering Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
67
Growth
67
Size
63
Value
51
Momentum
40
Issuance
34
Revisions
34
Volatility
26
Accruals
25

Quality (67): The business earns solid, repeatable profits on what it owns.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Jan 26Apr 26Jul 26Oct 26IMRXHigh $30Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $12Median $16High $30

The green dot is the last close — the median target sits +287.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026HC Wainwright & Co.InitiatesBuy$14
20 July 2026NeedhamMaintainsBuy$11 → $18
20 July 2026NeedhamMaintainsBuy—
8 July 2026Cantor FitzgeraldInitiatesOverweight—
8 July 2026Cantor FitzgeraldInitiatesOverweight—
19 May 2026Chardan CapitalMaintainsBuy—
9 Mar 2026NeedhamReiteratesBuy—
13 Nov 2025Chardan CapitalMaintainsBuy—
31 Oct 2025Leerink PartnersInitiatesOutperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
26 Sept 2025Chardan CapitalMaintainsBuy—
25 Sept 2025OppenheimerMaintainsOutperform—
15 Sept 2025NeedhamMaintainsBuy—
26 Aug 2025NeedhamReiteratesBuy—
14 Aug 2025Chardan CapitalMaintainsBuy—
18 June 2025Chardan CapitalMaintainsBuy—
18 June 2025MizuhoMaintainsOutperform—
18 June 2025NeedhamReiteratesBuy—
5 June 2025NeedhamReiteratesBuy—
7 May 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IMRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Immuneering Corp. returned −38.4% against +13.6% for the S&P 500, dividends included.

IMRX vs S&P 500, last 12 monthsTotal return, rebased to 100
5060708090100110120Jan 26Apr 26Jul 26Oct 26IMRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Immuneering Corp. (IMRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
−1.6×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.1%

Higher than 21% of US stocks

Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immuneering Corp. (IMRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immuneering Corp. has a market value of $247.8M and an enterprise value of $101.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.3M.

  • Diluted earnings per share, trailing twelve months: $−1.04.

  • Free cash flow in the twelve months to 30 June 2026: −$57.0M.

  • Shares outstanding: 64.7M.

  • Trailing P/E: −3.0×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immuneering Corp. employs 57 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

IMRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMRXImmuneering Corp.$247.8M36
LCTXLineage Cell Therapeutics, Inc.$259.1M61
ABEOAbeona Therapeutics, Inc.$259.6M43
IFRXInflaRx NV$254.8M9
OCGNOcugen, Inc.$262.8M24
FATEFate Therapeutics, Inc.$252.3M96
CABACabaletta Bio, Inc.$247.8M21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immuneering Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMRX news & analysis

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

GlobeNewsWire · 26 Oct 2026neutral

Immuneering presented the design and methodology of its ongoing global, randomized Phase 3 MAPKeeper 301 trial at the ESMO Congress 2026. The trial is evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel against standard-of-care gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, with overall survival as its primary endpoint.

Why it matters — The presentation provides an update on the design of Immuneering’s pivotal trial evaluating atebimetinib in metastatic pancreatic cancer.

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewsWire · 2 Oct 2026positive

Immuneering announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 4-8, 2026, in Phoenix, AZ. The poster demonstrates that atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors, providing mechanistic rationale for a planned Phase 2 study of atebimetinib combined with PD-1 blockade in lung cancer patients.

Why it matters — The preclinical data supporting atebimetinib's combination with PD-1 blockade strengthens the scientific rationale for Immuneering's upcoming Phase 2 study in lung cancer.

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer

GlobeNewsWire · 28 Sept 2026positive

Immuneering presented data at the 2026 AACR Conference on pancreatic cancer supporting atebimetinib's mechanisms designed to extend survival in the disease. The presentation highlighted that stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study compared to a benchmark study.

Why it matters — IMRX watchers would care because this new AACR data offers clinical evidence for atebimetinib's potential benefit in pancreatic cancer, a key development for the company's pipeline.

Immuneering to Present at the ESMO Congress 2026

GlobeNewsWire · 24 Sept 2026positive

Immuneering announced that a trial-in-progress abstract on its ongoing Phase 3 MAPKeeper 301 trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer has been accepted for poster presentation at the ESMO Congress 2026 in Madrid, October 23-27, 2026.

Why it matters — Presentation of the MAPKeeper 301 trial at a major oncology congress gives Immuneering exposure among the clinical community and independent visibility on the progress of its lead Phase 3 pancreatic cancer program.

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival

GlobeNewsWire · 10 Sept 2026positive

Immuneering announced it will present a poster at the AACR Conference on Pancreatic Cancer in September 2026, highlighting atebimetinib's dual mechanism for extended survival. The presentation expands on previously reported findings that 84% of evaluable first-line pancreatic cancer patients treated with atebimetinib plus mGnP maintained or gained weight at three months.

Why it matters — The presentation provides Immuneering with a key platform to showcase atebimetinib's clinical data, including new analyses on overall survival implications of preserving body mass and reducing tumor volume, which could influence investor and physician perception of the drug's potential.

FAQ

Frequently asked questions about IMRX stock

What is the IMRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Immuneering Corp. have a median 12-month price target of $16, with estimates ranging from $12 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMRX stock a buy right now?

Of the 7 analysts covering Immuneering Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immuneering Corp. 36 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMRX?

As at 28 Oct 2026, Immuneering Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (67 of 100).

Will IMRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +287.5% from the last close, and Ticker Nerd's factor model ranks Immuneering Corp. 36 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMRX stock forecast for 2030?

No analyst covering Immuneering Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $30 over the next 12 months.

How has IMRX stock performed over the past year?

Immuneering Corp. returned -38.4% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immuneering Corp. do?

Immuneering Corp. Class A Common Stock represents ownership in Immuneering Corporation, a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients.

What is the latest news on IMRX?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026". Immuneering presented the design and methodology of its ongoing global, randomized Phase 3 MAPKeeper 301 trial at the ESMO Congress 2026. The trial is evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel against standard-of-care gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, with overall survival as its primary endpoint.

Company

About Immuneering Corp.

Immuneering Corp. Class A Common Stock represents ownership in Immuneering Corporation, a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. Immuneering’s current work centers on a pipeline of drug candidates designed to address cancer through its computational drug discovery approach, including lead programs aimed at solid tumors and mutations associated with difficult-to-treat cancers. The company’s research platform supports the identification and development of therapies built to interfere with cellular signaling pathways, with an emphasis on oncology applications. Immuneering also operates in computational biology and translational bioinformatics, applying its scientific platform to advance drug discovery activities. Headquartered in Cambridge, Massachusetts, Immuneering Corporation serves the biotechnology and pharmaceutical sectors through its ongoing clinical development programs and research-driven approach to cancer medicine.

CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D. · 57 employees · United States · https://immuneering.com